Torrent Pharmaceuticals Ltd (TORNTPHARM) Q2FY27 Concall Summary - Sep-2026 Qtr
Key Takeaways
- Cost synergies from the JB merger are materializing faster than planned, with a significant portion of the INR 450 crore target expected within two years, not three.
- The company will increase its annual US filings to a high-single-digit number, funded by a sustained R&D spend of 4.0-4.5% of sales for 2-3 years.
- Management expects the overall JB business to return to double-digit growth in H2 FY27, following a transient slowdown due to integration activities in H1.
Performance Overview
- Torrent Pharmaceuticals Ltd posted strong consolidated revenue and EBITDA growth, driven by the robust performance of its base business.
- The integration of the recently merged JB business is progressing, with cost synergies tracking ahead of plan, though it caused a transient impact on JB's topline.
- The core India business demonstrated significant outperformance, growing at 20% versus the Indian Pharmaceutical Market (IPM) growth of 12%.
- International business performance was mixed, with strong double-digit growth in Brazil counteracted by a decline in Germany due to tender losses and supply disruptions.
- The company is increasing its R&D spend to accelerate filings in the US market, aiming to recover lost momentum from previous operational issues.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.
Tone & Disclosure
Log in to Stocksigma to read the Tone & Disclosure section of this summary.